October 16, 2018
UC researchers are part of national study comparing methods of increasing dangerously low blood pressure levels in sepsis patients.
June 1, 2020
Dr. Carl Fichtenbaum of the Division of Infectious Diseases at the UC College of Medicine was interviewed by CNBC on the safest ways to vacation this summer in the midst of COVID-19.
November 13, 2020
A University of Cincinnati immunologist is recommending that individuals with contact dermatitis choose facial masks made without elastic or rubber that allow them to stay safe in the midst of COVID-19 while avoiding possible allergic reactions. Yashu Dhamija, MD, a first-year fellow in the UC Division of Immunology, Allergy, and Rheumatology, presented his findings in an abstract while discussing a medically challenging case at the virtual American College of Allergy, Asthma and Immunology (ACAAI) scientific meeting held November 13-15.
March 31, 2022
Research from UC shows renewed hope in reducing hospitalizations from COVID-19 through the use of convalescent plasma when given early in the disease course. The study was published in the New England Journal of Medicine.
August 26, 2021
Researchers at the University of Cincinnati and UC Health have administered a first-of-its-kind potential COVID-19 therapy. The first dosing was administered to a patient at UC Medical Center in Cincinnati on Aug. 17.
September 28, 2021
The University of Cincinnati College of Medicine is opening what it calls a “heart bank” to collect tissue samples that can be used by researchers. Those samples will be stored in a biorepository to provide a potentially valuable resource to help researchers find answers to scientific questions.
January 25, 2022
Women who receive a kidney transplant have low rates of contraceptive use according to new research from the University of Cincinnati. The study, published in the Journal of Nephrology, finds an overall contraceptive use rate of 9.5% among women with kidney transplants in the United States.
February 15, 2022
The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications. ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States through its website.